journal
MENU ▼
Read by QxMD icon Read
search

Journal of Kidney Cancer and VHL

journal
https://www.readbyqxmd.com/read/30109169/characterisation-of-the-morphological-functional-and-molecular-changes-in-sunitinib-resistant-renal-cell-carcinoma-cells
#1
Hossam Kamli, Gobe C Glenda, Li Li, David A Vesey, Christudas Morais
Sunitinib resistance is a major clinical problem hampering the treatment of renal cell carcinoma (RCC). Studies on the comprehensive characterisation of morphological, functional and molecular changes in sunitinib-resistant RCC cells are lacking. The aim of the current study was to develop sunitinib resistance in four human RCC cell lines (786-0, Caki-1, Caki-2 and SN12K1), and to characterise the changed cell biology with sunitinib resistance. RCC cells were made resistant by continuous, chronic exposure to 10 μM of sunitinib over a period of 12 months...
2018: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/29911000/vhl-associated-optic-nerve-hemangioblastoma-treated-with-stereotactic-radiosurgery
#2
Hiroshi Kanno, Seiki Osano, Masamichi Shinonaga
Central nervous system hemangioblastomas are generally restricted to the cerebellum, spinal cord, and brainstem. Supratentorial hemangioblastomas are uncommon, and optic nerve hemangioblastomas are extremely rare, with fewer than 25 reports including this case. In this report, we present the case of a 36-year-old woman with von Hippel-Lindau (VHL) disease who presented with progressive diminution of vision in the left eye due to a retrobulbar optic nerve hemangioblastoma. The patient had a history of cerebellar/spinal hemangioblastomas and pancreatic cysts, and her father and brother were patients with VHL disease...
2018: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/29682443/checkpoint-kinase-2-chek2-mutation-in-renal-cell-carcinoma-a-single-center-experience
#3
Joanna Huszno, Zofia Kołosza
Renal cell carcinoma (RCC) occurs in sporadic and heritable forms. Genetic mutations have been identified as risk factors in 1-2% of RCC. The aim of this study was to evaluate I157T and CHEK2*1100delC mutations of checkpoint kinase 2 (CHEK2) gene in RCC. Medical records of 40 clear cell RCC patients who had genetic tests and consultation at the Genetic Outpatient Clinic, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland, were reviewed retrospectively. Mutation profile was assessed by ASA-PCR and RFLP-PCR techniques...
2018: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/29468108/nivolumab-in-renal-cell-carcinoma-current-trends-and-future-perspectives
#4
REVIEW
Cesar E Ochoa, Richard W Joseph
Targeted agents form the backbone of most therapeutic strategies in advanced renal cell carcinoma (aRCC) but ultimately resistance develops and toxicity often leads to discontinuation of treatment, limiting the clinical benefits of these treatments. Nivolumab, a fully human IgG4 anti-PD-1 antibody, selectively blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2 and provides a novel therapy option for patients with aRCC. In 2015, the pivotal phase III study CheckMate 025 led to the Food and Drug Administration approval of nivolumab in patients with aRCC who had received prior anti-angiogenic therapy, and in 2017, the phase III study CheckMate 214 showed that combined immunotherapy with nivolumab plus ipilimumab resulted in greater objective response rate and prolonged progression-free survival when compared with sunitinib in intermediate- and poor-risk patients with previously untreated aRCC...
2018: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/29468107/contrast-enhanced-ultrasound-guided-radiofrequency-ablation-of-renal-tumors
#5
REVIEW
Dan O'Neal, Tal Cohen, Cynthia Peterson, Richard G Barr
Although only limited long-term studies evaluating thermal ablation of renal masses have been performed, it appears that thermal ablation has a comparable 5-year success rate to that of partial or total nephrectomy. This technique is often used in patients who are not good candidates for partial or total nephrectomy. Contrast-enhanced ultrasound (CEUS) has been recently approved by the Food and Drug Administration for characterization of focal liver lesions in adults and pediatric patients. CEUS can be used off label for renal applications and has been used for years in Europe and Asia...
2018: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/29354391/extensive-metastatic-sarcomatoid-renal-cell-carcinoma-evaluated-by-18-f-fdg-pet-ct-a-case-report-and-review-of-literature
#6
Dominique Fuser, Matthew L Hedberg, Louis P Dehner, Farrokh Dehdashti, Barry A Siegel
Sarcomatoid renal cell carcinoma (sRCC) is a highly aggressive form of dedifferentiated renal cell carcinoma. We report a 62-year-old man who presented with respiratory symptoms and a lung mass on chest computed tomography (CT). The patient underwent positron emission tomography/computed tomography (PET/CT) with 18 F-fluorodeoxyglucose (18 F-FDG) and was found to have extensive metastatic disease. Based on the history and imaging findings, there were possible primary malignancies, including bronchogenic carcinoma, melanoma, or an aggressive lymphoma...
2018: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/29090118/the-risks-of-renal-angiomyolipoma-reviewing-the-evidence
#7
REVIEW
Raouf M Seyam, Waleed K Alkhudair, Said A Kattan, Mohamed F Alotaibi, Hassan M Alzahrani, Waleed M Altaweel
Renal angiomyolipoma (RAML), though a rare benign tumor, may impose a significant morbidity or even mortality due to its unique characteristics and the complications subsequent to its treatment. The classic tumor variant is composed of smooth muscular, vascular, and fatty components. The most straightforward diagnosis is when the fat component is abundant and gives a characteristic appearance on different imaging studies. In fat-poor lesions, however, the diagnosis is difficult and presumed a renal cell carcinoma...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/29090117/modern-pathologic-diagnosis-of-renal-oncocytoma
#8
REVIEW
Sara E Wobker, Sean R Williamson
Oncocytoma is a well-defined benign renal tumor, with classic gross and histologic features, including a tan or mahogany-colored mass with central scar, microscopic nested architecture, bland cytology, and round, regular nuclei with prominent central nucleoli. As a result of variations in this classic appearance, difficulty in standardizing diagnostic criteria, and entities that mimic oncocytoma, such as eosinophilic variant chromophobe renal cell carcinoma and succinate dehydrogenase-deficient renal cell carcinoma, pathologic diagnosis remains a challenge...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28890865/functional-imaging-of-paragangliomas-with-an-emphasis-on-von-hippel-lindau-associated-disease-a-mini-review
#9
REVIEW
Ioannis Ilias, Georgios Meristoudis
Few reports have presented data and results on functional (i.e., nuclear medicine) imaging of paragangliomas and pheochromocytomas (PGLs/PHEOs) for von Hippel-Lindau (VHL) patients. Nuclear medicine localization modalities for chromaffin tumors can be specific or nonspecific. Specific methods make use of the expression of the human norepinephrine transporter (hNET) and vesicular monoamine transporters (VMATs) by these tumors. These permit the use of radiolabeled ligands that enter the synthesis and storage pathway of catecholamines...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28868236/management-strategies-and-outcomes-for-vhl-related-craniospinal-hemangioblastomas
#10
REVIEW
Christ Ordookhanian, Paul E Kaloostian, Samer S Ghostine, Philippe E Spiess, Arnold B Etame
Hemangioblastomas are rare and benign tumors accounting for less than 2% of all central nervous system (CNS) tumors. The vast majority of hemangioblastomas occur sporadically, whereas a small number of cases, especially in younger patients, are associated with Von Hippel-Lindau (VHL) syndrome. It is thought that loss of tumor suppressor function of the VHL gene results in stabilization of hypoxia-inducible factor alpha with downstream activation of cellular proliferative and angiogenic genes that promote tumorigenesis...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28785532/a-review-of-von-hippel-lindau-syndrome
#11
REVIEW
Neha Varshney, Amanuel A Kebede, Harry Owusu-Dapaah, Jason Lather, Manu Kaushik, Jasneet S Bhullar
Von Hippel-Lindau syndrome (VHL) is a familial neoplastic condition seen in approximately 1 in 36,000 live births. It is caused by germline mutations of the tumor suppressor gene VHL, located on the short arm of chromosome 3. While the majority of the affected individuals have a positive family history, up to 20% of cases arise from de novo mutations. VHL syndrome is characterized by the presence of benign and malignant tumors affecting the central nervous system, kidneys, adrenals, pancreas, and reproductive organs...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28752023/trends-in-the-management-of-small-renal-masses-a-survey-of-members-of-the-endourological-society
#12
Anand Mohapatra, Aaron M Potretzke, John Weaver, Barrett G Anderson, Joel Vetter, Robert S Figenshau
Treatment modalities for small renal masses (SRMs) include open or minimally invasive radical or partial nephrectomy, and laparoscopic or percutaneous ablations. Members of the Endourological Society were surveyed to evaluate how practitioner and clinical practice characteristics may be associated with the management of SRMs over time. The survey assessed characteristics of urologists (recency of residency and fellowship training, clinical practice type and location, and treatment modalities available) and their management of SRMs over the past year and over the course of the year 5 years prior...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28752022/ultrasound-imaging-of-cystic-nephroma
#13
REVIEW
Federico Greco, Eliodoro Faiella, Domiziana Santucci, Delia De Lisi, Gianguido Lo Vullo, Bruno Beomonte Zobel, Rosario Francesco Grasso
Cystic nephroma is a rare, benign multicystic lesion of the kidney. This tumor occurs both in children and in adults. In children, it is highly prevalent in males; in adults, it is more frequent in women. The term "cystic nephroma" represents two apparently different entities: pediatric cystic nephroma, a benign form thought to originate from metanephric tissue, and adult cystic nephroma, considered as a lesion of mixed epithelial stromal tumor. The clinical presentation may be a palpable mass or nonspecific symptoms such as abdominal pain, hematuria, and urinary tract infections...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28725541/delayed-intervention-of-small-renal-masses-on-active-surveillance
#14
Mohit Gupta, Michael L Blute, Li-Ming Su, Paul L Crispen
Although surgical excision is the standard of therapy for small renal masses (SRMs), there is a growing recognition of active surveillance as an option in select patients who are poor surgical candidates or who have shorter life expectancy. A number of patients on expectant management, however, subsequently advance to definitive therapy. In this study, we systematically reviewed the literature and performed a pooled analysis of active surveillance series to evaluate the rate and indications for definitive treatment after initiating a period of active surveillance...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28725540/the-pathology-and-molecular-genetics-of-sarcomatoid-renal-cell-carcinoma-a-mini-review
#15
REVIEW
Shuanzeng Wei, Tahseen Al-Saleem
Sarcomatoid renal cell carcinoma is a highly aggressive tumor. It is not a distinct histologic entity as it can be found in any subtypes of renal cell carcinoma. Recent molecular and genetic evidence suggest that sarcomatoid component is transformed from a common progenitor of the associated renal cell carcinoma, and the TP53 gene plays a pivotal role in this process. The presence of sarcomatoid carcinoma indicates poor prognosis, which also correlates with the amount of the sarcomatoid component. Therefore, the presence and quantity of sarcomatoid component should be reflected in pathology reports...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28725539/the-evolving-treatment-landscape-of-advanced-renal-cell-carcinoma-in-patients-progressing-after-vegf-inhibition
#16
REVIEW
Pedro C Barata, Moshe C Ornstein, Jorge A Garcia
Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding existing data on subsequent therapies is crucial to define an optimal treatment sequence following first-line failure. This review examines the data supporting currently approved agents in this setting and provides a framework for decision-making regarding treatment sequencing beyond first-line therapy with VEGFR TKIs...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28725538/a-rare-case-of-solitary-kidney-metastasis-following-primary-laryngeal-squamous-cell-carcinoma
#17
Sharon Del Vecchio, Robert Ellis, Kylie Gallagher, Keng Lim Ng, Li Ma, Geoffrey Strutton, Simon Wood
Laryngeal cancer is the 14th most common malignancy worldwide, and its common subtype squamous cell carcinoma (SCC) is highly associated with tobacco use and long-term alcohol consumption. The incidence of distant metastasis from a primary laryngeal cancer has been reported to be very low, between 6.5% and 8.5%, according to published tumour registry data. Distant metastases of laryngeal SCC most commonly involve the lung, liver, bone and mediastinum, seldom involving the kidney. Renal metastasis has been well established in many other cancers such as lymphoma, lung, breast and gastric carcinoma...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28725537/the-emerging-role-of-histone-demethylases-in-renal-cell-carcinoma
#18
REVIEW
Xiaoqiang Guo, Qiaoxia Zhang
Renal cell carcinoma (RCC), the most common kidney cancer, is responsible for more than 100,000 deaths per year worldwide. The molecular mechanism of RCC is poorly understood. Many studies have indicated that epigenetic changes such as DNA methylation, noncoding RNAs, and histone modifications are central to the pathogenesis of cancer. Histone demethylases (KDMs) play a central role in histone modifications. There is emerging evidence that KDMs such as KDM3A, KDM5C, KDM6A, and KDM6B play important roles in RCC...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28405545/maslinic-acid-inhibits-proliferation-of-renal-cell-carcinoma-cell-lines-and-suppresses-angiogenesis-of-endothelial-cells
#19
Parth Thakor, Wenzhe Song, Ramalingam B Subramanian, Vasudev R Thakkar, David A Vesey, Glenda C Gobe
Despite the introduction of many novel therapeutics in clinical practice, metastatic renal cell carcinoma (RCC) remains a treatment-resistant cancer. As red and processed meat are considered risk factors for RCC, and a vegetable-rich diet is thought to reduce this risk, research into plant-based therapeutics may provide valuable complementary or alternative therapeutics for the management of RCC. Herein, we present the antiproliferative and antiangiogenic effects of maslinic acid, which occurs naturally in edible plants, particularly in olive fruits, and also in a variety of medicinal plants...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28405544/predictive-factors-for-second-line-therapy-in-metastatic-renal-cell-carcinoma-a-retrospective-analysis
#20
Hendrik Eggers, Philipp Ivanyi, Mareike Hornig, Viktor Grünwald
Currently, about 50% of patients with metastatic renal cell carcinoma (mRCC) receive a second-line therapy. Therefore, the choice at each subsequent treatment line remains an important issue. In this retrospective study, we sought to identify pretreatment clinical parameters that could predict the likelihood of a patient receiving a second-line therapy. One hundred and sixty-one mRCC patients who received targeted therapy were evaluated. Descriptive statistics, Kaplan-Meier overall survival (OS), Cox regression, and binary logistic regression models were used for data analysis...
2017: Journal of Kidney Cancer and VHL
journal
journal
54244
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"